Literature DB >> 31053882

Plasma concentrations and ACE-inhibitory effects of tryptophan-containing peptides from whey protein hydrolysate in healthy volunteers.

Melanie Martin1, Diana Hagemann2, Thinh Trung Nguyen2, Lisa Schwarz2, Sherif Khedr3, Mats Leif Moskopp3, Thomas Henle2, Andreas Deussen3.   

Abstract

PURPOSE: The tryptophan-containing dipeptides isoleucine-tryptophan (IW) and tryptophan-leucine (WL) are angiotensin-converting enzyme (ACE)-inhibitors in vitro. These peptides are released by enzymatic hydrolysis of bovine whey protein. To exhibit ACE inhibition in vivo, peptides need to be absorbed into the circulatory system. This study aimed to determine the in vivo ACE-inhibitory potency of a whey protein hydrolysate (MPH), containing IW and WL, and to quantify plasma concentrations of these peptides after oral administration of MPH in healthy volunteers. Additionally, changes in blood pressure were investigated.
RESULTS: After intake of 5 and 50 g MPH, plasma ACE activity was reduced to 86.4 ± 5.9 and 75.1 ± 6.9% of baseline activity, respectively. Although a clear ACE inhibition was measured, no effect on blood pressure was seen. Basal plasma concentrations of the tryptophan-containing dipeptides were 2.8 ± 0.7 nM for IW and 10.1 ± 1.8 nM for WL. After intake of 5-50 g MPH, peptide concentrations were dose dependently elevated to values between 12.5 ± 8.4 and 99.1 ± 58.7 nM for IW and 15.0 ± 4.3-34.9 ± 19.4 nM for WL. Administration of intact whey protein showed a minor ACE inhibition, probably caused by release of inhibitory peptides during gastrointestinal digestion. The increase of WL in plasma after intake of intact protein was similar to that determined after intake of MPH. In contrast, resulting IW concentrations were much lower after intake of intact whey protein when compared to MPH administration.
CONCLUSION: After intake of MPH, plasma ACE activity decreased in parallel to the increase of IW and WL plasma concentrations. However, the resulting peptide concentrations cannot fully explain the reduction of ACE activity in plasma with a direct enzyme inhibition. Therefore, this study points to a gap in the understanding of the inhibitory action of these peptides in vivo. Thus, to further develop innovative food additives with ACE activity diminishing capabilities, it appears mandatory to better characterize the mode of action of these peptides.

Entities:  

Keywords:  ACE-inhibitory peptides; Angiotensin converting enzyme; Antihypertensive peptides; Arterial hypertension; Whey protein

Year:  2019        PMID: 31053882     DOI: 10.1007/s00394-019-01974-x

Source DB:  PubMed          Journal:  Eur J Nutr        ISSN: 1436-6207            Impact factor:   5.614


  32 in total

1.  Identification and inhibitory properties of multifunctional peptides from pea protein hydrolysate.

Authors:  Huan Li; Rotimi E Aluko
Journal:  J Agric Food Chem       Date:  2010-10-07       Impact factor: 5.279

Review 2.  Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation.

Authors:  Robert M Carey; Helmy M Siragy
Journal:  Endocr Rev       Date:  2003-06       Impact factor: 19.871

3.  Tissue distribution of antihypertensive dipeptide, Val-Tyr, after its single oral administration to spontaneously hypertensive rats.

Authors:  Toshiro Matsui; Miho Imamura; Hiromi Oka; Katsuhiro Osajima; Ko-Ichi Kimoto; Terukazu Kawasaki; Kiyoshi Matsumoto
Journal:  J Pept Sci       Date:  2004-09       Impact factor: 1.905

4.  Linking oxidative stress, the renin-angiotensin system, and hypertension.

Authors:  Camilla Fanelli; Roberto Zatz
Journal:  Hypertension       Date:  2011-01-31       Impact factor: 10.190

Review 5.  The role and pathophysiological relevance of membrane transporter PepT1 in intestinal inflammation and inflammatory bowel disease.

Authors:  Sarah A Ingersoll; Saravanan Ayyadurai; Moiz A Charania; Hamed Laroui; Yutao Yan; Didier Merlin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-12-22       Impact factor: 4.052

6.  Intestinal peptide transport: ex vivo uptake studies and localization of peptide carrier PEPT1.

Authors:  D A Groneberg; F Döring; P R Eynott; A Fischer; H Daniel
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2001-09       Impact factor: 4.052

Review 7.  Secondary hypertension: evaluation and treatment.

Authors:  B E Akpunonu; P J Mulrow; E A Hoffman
Journal:  Dis Mon       Date:  1996-10       Impact factor: 3.800

Review 8.  Molecular and integrative physiology of intestinal peptide transport.

Authors:  Hannelore Daniel
Journal:  Annu Rev Physiol       Date:  2004       Impact factor: 19.318

9.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

Review 10.  Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues.

Authors:  Claudio Borghi; Francesco Rossi
Journal:  High Blood Press Cardiovasc Prev       Date:  2015-09-24
View more
  1 in total

Review 1.  Potential Relevance of Bioactive Peptides in Sports Nutrition.

Authors:  Daniel König; Jan Kohl; Simon Jerger; Christoph Centner
Journal:  Nutrients       Date:  2021-11-10       Impact factor: 5.717

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.